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In chronic renal failure, hypoxia of renal tissue is thought to be the common ﬁnal pathway leading to end-stage renal failure.
In this study the eﬀects of hachimijiogan, a Kampo formula, were studied with respect to hypoxia-inducible factor (HIF). Using
remnantkidneyrats,westudied the eﬀects ofhachimijiogan on renal function in comparisonwith angiotensinII receptor blocker.
The result showed that oral administration of hachimijiogan for seven days suppressed urinary protein excretion and urinary 8-
OHdG, a marker of antioxidant activity, equally as well as oral administration of candesartan cilexetil. In contrast, the protein
volume of HIF-1α in the renal cortex was not increased in the candesartan cilexetil group, but that in the hachimijiogan group
was increased. In immunohistochemicalstudies as well, the expression of HIF-1α of the high-dose hachimijiogan group increased
compared to that of the control group. Vascular endothelial growth factor and glucose transporter 1, target genes of HIF-1α,w e r e
also increased in the hachimijiogan group. These results suggest that hachimijiogan produces a protective eﬀect by a mechanism
diﬀerent from that of candesartan cilexetil.
1.Introduction
In recent years, it has been clear that chronic kidney disease
(CKD)is an important risk factor for cardiovascular diseases
and mortality and has been the focus of considerable
attention [1]. The number ofdialysis patients caused by end-
stage renal disease has been increasing worldwide, regardless
of the advances in treatments, such as a protein- and
sodium-restricted diet, medicines containing angiotensin II
receptor blocker (ARB), and kidney transplants [2]. There
are various causes for the early stage of CKD, but there
is a common pathway in advanced CKD as represented
by interstitial ﬁbrosis, glomerular sclerosis, and nephron
destruction [3]. The kidney is sensitive to oxygen supply
and is prone to sustaining damage from hypoxia. In recent
years, it has been reported that chronic hypoxia in the
kidneyistheﬁnalcommonpathwaytoend-stagerenalfailure
[4, 5]. Thus, therapeutic approaches against hypoxic injury
in CKD patients are considered important for preventing
the worsening of CKD. As a biological defense mechanism
against tissue hypoxia, hypoxia-inducible factor (HIF), a
heterodimeric transcription factor, plays an essential role.
Activation of HIF stimulates numerous downstream target
genes and protects tissue from hypoxia [6]. This eﬀect is
suggested by reports, which showed that cobalt ameliorates
renal injury of renal disease model rats [7], and vascular2 Evidence-Based Complementary and Alternative Medicine
endothelial growth factor (VEGF) enhances glomerular
capillary repair and accelerates resolution of experimentally
induced glomerulonephritis [8].
Hachimijiogan, which we used in this study, is a Kampo
formula created more than 1800 years ago. It is composed
of eight crude drugs: Cinnamomi Cortex, Aconiti Japonici
Tuber, Rehmanniae Radix, Corni Fructus, Dioscoreae Rhi-
zoma, Alismatis Rhizoma, Moutan Cortex, and Hoelen. It
has been clinically used to treat many symptoms, such as
lumbago, pollakisuria, cold hands and feet, nephritis, and
so on [9]. In basic research, it has been reported that
hachimijiogan inhibits the progression of renal dysfunction
in diabetic nephropathy model rats and 5/6 nephrectomized
model rats. As the mechanism of its action, reduction
of uremic toxins associated with antioxidant activity and
positive eﬀects on organic change of the kidney have been
reported [10, 11].
However, there are no studies reporting the eﬀect of
hachimijiogan on HIF. Therefore, we examined the eﬀect of
hachimijiogan in comparison to ARB, a mainstream drug
for renal disorder, on renal dysfunction from the aspect
of hypoxic injury using 5/6 nephrectomized rats, in which
tissue hypoxia causes progression of renal failure [12, 13].
2.Materialsand Methods
2.1. Materials. The bulk extract of hachimijiogan (batch
number 2060007020), which is approved for medical use
in Japan, was purchased from Tsumura Co. Ltd. (Tokyo,
Japan). It consists of eight herbs: 6.0g of Rehmanniae Radix
(Rehmannia glutinosa Liboschitz var. purpurea Makino),
3.0g of Corni Fructus (Cornus oﬃcinalis Siebold et Zuc-
carini), 3.0g of Dioscoreae Rhizoma (Dioscorea japonica
Thunberg), 3.0g of Alismatis Rhizoma (Alisma orientale
Juzepczuk), 3.0g of Hoelen (Poria cocos Wolf), 3.0g of
Moutan Cortex (Paeonia suﬀruticosa Andrews), 2.5g of
Cinnamomi Cortex (Cinnamomum cassia Blume), 1.0g of
Aconiti Tuber (Aconitum carmichaeli Debeaux).
Candesartan cilexetilwas obtainedfrom Takeda Pharma-
ceutical Company Ltd. (Osaka, Japan).
2.2. Three-Dimensional HPLC Analysis of Hachimijiogan.
For analysis of the components of hachimijiogan, aqueous
extract (1g) was extracted with 20mL methanol under
ultrasonication for30min. The solution was ﬁltered through
a membrane ﬁlter (0.45μm) and then subjected to high-
performance liquid chromatography (HPLC) analysis using
a TSK-GEL ODS-80TS column (ϕ4.6 × 250mm, Tosoh,
Tokyo, Japan) with an LC 10AD pump and an SPD-
M10A absorbance detector. The elution solvents were (A)
0.05M AcOH-AcONH4 and (B) CH3CN, and the column
was eluted with a linear gradient of, by volume, 90% A
and 10% B changing over 60min to 100% B. The ﬂow
rate was 1.0mL/min, and the eﬄuent from the column
was monitored and processed into three-dimensional data
by an SPD-M10A array detector. All assigned peaks were
identiﬁed by comparing their UV spectral data with those of
coinjected authentic samples using the Class LC-10 Version
1.62 software package (Shimadzu, Kyoto, Japan). The three-
dimensional HPLC proﬁle of hachimijiogan extract is shown
in Figure 1. The major components of hachimijiogan were
morroniside, loganin, paeoniﬂorin, penta-O-galloyl glucose,
benzoylmesaconine, benzoylpaeoniﬂorin, 16-ketoalisol A,
paeonol, cinnamic acid, and cinnamaldehyde.
2.3. Animals and Treatments of Animals. All experimental
procedureswereperformed inaccordancewith thestandards
established by the “Guidefor the Care and Use of Laboratory
Animals at the University of Toyama”. Fifty 6-week-old male
Sprague-Dawley rats were purchased from Japan SLC Inc.
(Hamamatsu, Japan) and keptin an automatically controlled
room (temperature about 23◦C and humidity about 60%)
with a conventional dark/light cycle. The animals were
kept in metabolic cages, and 24-hour urine samples were
collected. Blood pressure was determined by tail cuﬀ system
(MK2000, Muromachi Kikai Co., Ltd., Tokyo, Japan) in
a conscious state. At 7 weeks old, 40 rats underwent 5/6
nephrectomy under anesthesia with sodium pentobarbital
(50mg/kg body weight, i.p.) by ablation of approximately
2/3 of the left kidney, and then removal of the right kidney
by ligation of renal artery, vein, and ureter 1 week later.
After recovery from the operation (after 1 week), the 5/6
nephrectomized (5/6Nx) rats were randomly divided into
four groups (control and three treatment groups, n =
10/group). One more group of rats had undergone a sham
operation (n = 10). During the experimental period, all
groups were fed a standard chow. The sham and control
groups were fed water, and the other three surgical groups
were fed a solution of hachimijiogan extract orally at a dose
of 220mg/kg body weight/day (low-dose hachimijiogan),
660mg/kg body weight/day (high-dose hachimijiogan), or a
solution of candesartan cilexetil orally at a dose of 3mg/kg
body weight/day, respectively, by gastric gavage. These doses
of hachimijiogan for rats were approximately 3 times and
10 times the human dose of hachimijiogan. After 7 days of
treatment, the rats were sacriﬁced, and blood samples were
obtained. The kidneys were removed from each rat, frozen
quickly, and kept at −80◦C until analysis.
2.4. Analysis of Serum and Urine Samples. Serum levels of
Albumin were determined by SRL, Inc. (Tokyo, Japan).
Serum levels of urea nitrogen (BUN) and creatinine (s-
Cre) were determined using commercial kits (BUN Kainos
and CRE-EN Kainos purchased from Kainos Laboratories,
Inc., Tokyo, Japan). Urinary protein (u-Pro) excretion levels
were determined using commercial reagents (Micro TP-test,
Wako Pure Chemical, Osaka, Japan). Creatinine clearance
(Ccr) was calculated on the basis of urinary creatinine,
serum creatinine, urine volume, and body weight using
the following equation: Ccr (mL/(kg body weight)/min)
= {urinary Cre (mg/dL) × urine volume (mL)/serum
Cre/(mg/dL)}×{1,000/body weight (g)}×{1/1,440(min)}.
8-Hydroxy-deoxyguanosine (8-OHdG) content in 24-hour
urine samples was measured by ELISA kit (8-OHdG Check,
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Figure 1: Chemical proﬁle of hachimijiogan analyzed by three-dimensional HPLC.
2.5. Real-Time RT-PCR. Total RNA was prepared using the
RNeasy Mini kit (QIAGEN, Valencia, CA, USA).First-strand
cDNAwassynthesized bySuperScriptIIreversetranscriptase
(Invitrogen, Carlsbad, CA, USA). cDNA was ampliﬁed
quantitativelyusingSYBRPremixExTaq(TaKaRa-Bio,Otsu,
Japan). The primer sequences are summarized in Table 1.
Real-time quantitative RT-PCR was performed using an ABI
Prism 7300 sequence detection system (Applied Biosystems,
Foster City, CA, USA). All data were normalized to β-actin
mRNA.
2.6. Protein Preparation and Western Blotting. The cortex
was dissected from the frozen kidney and homogenized
in buﬀer A (10mM HEPES pH 7.9, 10mM KCl, 0.1mM
EDTA, 0.1 mM EGTA, 1 mM DTT, 1 mM PMSF, 20 mM β-
glycerophosphate, 0.1mM sodium orthovanadate, 10μg/mL
aprotinin, and 10μg/mL leupeptin) and chilled on ice for
15min. Next, 25μL of 10% Nonidet P-40 was added and the
suspension was vigorously vortexed for 10s and kept on ice
for 5min. The nuclear pellets were washed with 100μLo f
buﬀer A and suspended in 50μLo fb u ﬀer C (20mM HEPES
pH 7.9, 0.4M NaCl, 1mM EDTA, 1mM EGTA, 1mM DTT,
1mM PMSF , 20mM β-glycerophosphate, 1mM sodium
orthovanadate, 10μg/mL aprotinin, 10μg/mL leupeptin).
T h em i x t u r ew a sk e p to ni c ef o r1 5 m i nw i t hf r e q u e n t
agitation. Nuclear extracts were prepared by centrifugation
at 15,000rpm for 5min.
Kidney lysates were resolved by SDS-PAGE and trans-
ferred to Immobilon-P nylon membrane (Millipore, Bed-
ford, MA, USA). The membrane was treated with BlockAce
(DS pharma Co. Ltd., Suita, Japan) overnight at 4◦Ca n d
probed with primary antibodies. An antibody against HIF-
1α (H1alpha67) was purchased from Abcam (Cambridge,
UK). Lamin B was used as an internal control. Antibodies
against Lamin B (C-20) were purchased from Santa Cruz
Biotechnologies (Santa Cruz, CA, USA). Enhancer solutions
(Can Get Signal; Toyobo, Osaka, Japan) were used for the
dilution. The antibodies were detected using horseradish
peroxidase-conjugated antimouse and antigoat IgG (Dako
Cytomation, Glostrup, Denmark) and visualized with the
ECL system for Lamin B and ECL-plus for HIF-1α (GE
Healthcare, Buckinghamshire, UK).
2.7. Histology and Immunohistochemistry. Rats were deeply
anesthetized by an intraperitoneal injection of pentobarbital
sodium (50mg/kg body weight). Kidney was rapidly excised
and immediately immersed in 4% paraformaldehyde and
embedded in paraﬃn. Sections (5μm thick) were routinely
stained with hematoxylin and eosin. Mouse monoclonal
antibody against HIF-1α (H1alpha, 1:25 diluted; Novus4 Evidence-Based Complementary and Alternative Medicine
Table 1: Sequences for RT-PCR primers.
Genes Forward Reverse
β-actin GCCAACCGTGAAAAGATGAC AGGCATACAGGGACAACACA
VEGF TTACTGCTGTACCTCCAC ACAGGACGGCTTGAAGATA [12]
Glut-1 AGGTGTTCGGCTTAGACTC GAAGGGCAACAGGATACAC
VEGF: vascular endothelial growth factor, Glut-1: glucose transporter 1.
Biologicals, Littleton, CO, USA) was used for immunohis-
tochemical staining of kidney as previously described [14].
For detecting primary antibodies on rat tissue specimens,
M.O.M. kit (Vector, Burlingame, CA, USA) was used for
special blocking. Tissue sections were cut at 5 micrometers
from tissue blocks and placed on slides. After deparaﬃniza-
tion, sections were soaked in target retrieval solution (TRS,
pH6.1,DakoCytomation)inanonmetal-containing plastic-
made pressure cooker and irradiated in a microwave oven
for15minutes(maximum500W).Afterirradiation,sections
wererinsed underrunning waterfor2minutes, soakedin3%
H2O2 methanol solution for 5 minutes, and then soaked in
5% BSA for 1 minute. After that, M.O.M. mouse Ig blocking
reagent was applied and incubated for 1 hour. Primary
antibody was diluted to a previously determined optimal
concentration in M.O.M. diluent. The diluted antibody
was applied to the tissue sections in a moist chamber
and irradiated intermittently for 30 minutes (250W, 4
seconds on, 3 seconds oﬀ). After three washes with Tris-
buﬀered saline containing 1% Tween (TBS-T) for 5 minutes,
peroxidase-conjugated Envision kit for mouse (Envision-
PO, Envision System, Dako Cytomation) was used on the
appropriatespecimens in the moist chamber. Irradiation was
then performed intermittently for 30 minutes as described
above. After washing 5 times with TBS, the sections were
immersed in DAB solution (Sigma-Aldrich, St. Louis, MO,
USA) with H2O2 and counterstained with hematoxylin
(Dako Cytomation) and mounted under coverslips.
Immunopositivity for HIF-1α in the tubular cells of the
cortex wascountedusing 18 ﬁeldspergroup,and theaverage
number per ﬁeld was determined.
2.8. Statistical Analysis. All values were presented as mean
± S.D., and were analyzed by one-way analysis of variance
(ANOVA) followed by Dunnett’s test. P<. 05 was accepted
as statistically signiﬁcant.
3.Results
3.1. Body Weight, Kidney Weight, Blood Pressure, and Urinary
Volume. Table 2 s h o w st h ec h a n g e si nb o d yw e i g h t ,k i d n e y
weight,blood pressure and urinary volumeoftheratsduring
the 1-week experimental period. The ﬁnal body weights of
the 5/6Nx groups were signiﬁcantly lower than that of the
sham group. There were no signiﬁcant diﬀerences between
baseline and ﬁnal body weights in the 5/6Nx groups. The
remnant kidney weights among the 5/6Nx groups did not
change after the 1-week treatment. Blood pressures among
all groups also did not change during the 1-week treatment.
Urinary volumes of the 5/6Nx groups increased signiﬁcantly
compared to the sham group. There were no signiﬁcant
diﬀerencesbetween baseline and ﬁnal urinary volumesin the
5/6Nx groups.
3.2. Serum and Urine Biochemical Parameters. Table 3 shows
the eﬀects of hachimijiogan on serum and urine biochem-
ical parameters. BUN levels of the control and low-dose
hachimijiogan groups were signiﬁcantly higher than that of
the sham group. There were no signiﬁcant diﬀerences in
BUN levels among the four 5/6Nx groups. The s-Cre level
of the control group was signiﬁcantly higher than that of
the sham group. There were no signiﬁcant diﬀerences in s-
Cre levels among the four 5/6Nx groups. Urinary protein
excretion of the control group was signiﬁcantly increased
compared to that of the sham group, and those of the
high-dose hachimijiogan and candesartan cilexetil groups
were signiﬁcantly decreased compared to that of the control
group. Ccr levels of the four 5/6Nx groups were signiﬁcantly
decreased compared to thatofthe sham group. The 8-OHdG
level of the control group was signiﬁcantly higher than that
of the sham group, and those of the low-dose hachimijiogan,
high-dose hachimijiogan, and candesartan cilexetil groups
were signiﬁcantly lower than that of the control group.
3.3. Renal Cortical Hypoxia-Related Factors. The volumes of
HIF-1α protein of the four 5/6Nx groups were signiﬁcantly
increasedcomparedtothatoftheshamgroup,andthatofthe
high-dose hachimijiogan group was signiﬁcantly increased
compared to that of the control group (Figure 2(a)). Figures
2(b) and 2(c) show the eﬀects of hachimijiogan on renal
mRNA levels of VEGF and glucose transporter-1 (Glut-1).
In the high-dose hachimijiogan group, the mRNA levels of
VEGF and Glut-1 were signiﬁcantly increased compared to
those of the sham and control groups.
Immunohistochemical studies also showed that the
expression of HIF-1α of the high-dose hachimijiogan group
was increased compared tothat ofthe controlgroup (Figures
3(a)–3(e)). There was a signiﬁcantly large number of HIF-
1α-positive cells in the high-dose hachimijiogan group
compared to the control group (Figure 3(f)).
4.Discussion
Recently, as a ﬁnal common pathway of various renal
diseases, attention has been focused on tubulointerstitial
hypoxia. It has been reported that the hypoxia of renal tissue
was caused by decreasing peritubular capillary blood ﬂow
due to renal ﬁbrosis, abnormal production of vasoactiveEvidence-Based Complementary and Alternative Medicine 5
Table 2: Physiological data of experimental animals.








Baseline Final Baseline Final Baseline Final Baseline Final
Sham 297.1±11.0 325.5±12.0 0.311±0.04 121.4±14.2 113.7±10.8 56.4±13.5 62.6±16.2 5.7±3.1 6.4±2.8
Control 261.7±22.9 291.6±26.4∗ 0.331±0.05 124.3±5.8 127.7±8.2 69.7±6.7 59.1±12.2 20.3±6.6∗∗ 21.1±6.1∗∗
LD-HJG 253.6±17.6 275.9±24.3∗ 0.341±0.03 132.9±27.1 130.0±17.2 74.2±19.1 62.8±16.2 17.6±6.7∗∗ 14.1±6.3∗∗
HD-HJG 257.5±16.6 295.6±16.4∗ 0.354±0.04 122.8±15.6 126.3±8.9 70.1±17.3 56.9±6.1 20.6±8.3∗∗ 18.0±7.1∗∗
Candesartan 264.3±14.6 276.1±16.6∗ 0.343±0.03 121.4±14.6 119.7±16.2 70.9±15.8 58.5±13.1 20.2±13.4∗∗ 16.5±12.8∗∗
LD-HJG: low-dose hachimijiogan; HD-HJG: high-dose hachimijiogan.
Baseline: before drug administration; Final: after 1 week of drug administration.
Data represent mean ± S.D. (n = 8–10). ∗P <. 05, ∗∗P <. 01 versus sham group.
Table 3: Eﬀect of hachimijiogan on renal functional parameters.
s-Alb (mg/dL) BUN (mg/dL) s-Cre (mg/dL) u-Pro (mg/day) Ccr (mL/min/kgBW) 8-OHdG (ng/day)
Sham 834.8 ± 110.9 15.6 ± 1.9 0.32 ± 0.14 13.01 ± 7.29 5.03 ± 3.07 325.9 ± 106.5
Control 887.1 ± 67.4 50.6 ± 36.7∗∗ 1.44 ± 1.32∗∗ 35.34 ± 20.62∗∗ 1.88 ± 0.94∗∗ 840.4 ± 252.4∗∗
LD-HJG 895.8 ± 25.7 42.0 ± 27.1∗ 0.93 ± 0.59 25.15 ± 15.32 2.13 ± 1.40∗∗ 582.9 ± 201.8#
HD-HJG 833.9 ± 82.2 39.6 ± 25.7 0.87 ± 0.61 19.73 ± 5.41# 2.11 ± 0.86∗∗ 550.9 ± 210.5#
Candesartan 840.8 ± 92.5 33.8 ± 12.3 0.88 ± 0.49 15.41 ± 5.92## 1.65 ± 0.64∗∗ 484.2 ± 171.3##
LD-HJG: low-dose hachimijiogan; HD-HJG: high-dose hachimijiogan.
Data represent mean ± S.D. (n = 8–10).
∗P <. 05, ∗∗P <. 01 versus sham group.
#P <. 05, ##P <. 01 versus control group.
substance, anemia, and so on [15]. HIF, a heterogeneous
nuclear ribonucleoprotein, is an important defense factor
against tissue hypoxia. Activation of HIF and numerous
downstream target genes protect tissues from hypoxia [6].
Undernormoxic conditions, HIF-1α subunit is hydroxylated
by prolyl hydroxylase (PHD). Hydroxylation is promoted
by von Hippel-Lindau tumor suppressor protein binding to
HIF-1α subunit. As a result, HIF-1α subunit is destroyed
by proteasome. As PHD activity is decreased under hypoxic
condition, HIF-1α subunit heterodimerizes with the consti-
tutively expressed HIF-1β subunit. The heterodimeric HIF
translocates into the nucleus, activating gene transcriptions,
such asangiogenesis, cell metabolism, cell growth,apoptosis,
and so on [16]. However, it has been reported that activation
of HIF becomes less responsive to renal hypoxia in advanced
renal dysfunction [17, 18]. It has also been reported that oral
administration of cobalt chloride, which activates HIF, ame-
lioratesrenalinjuryindiabeticnephropathyofSHR/NDmer-
cp rats [7], and that VEGF plays an important role in
capillary repair in damaged glomeruli in glomerulonephritis
rats induced by injection of anti-Thy-1.1 antibody [8]. On
the basis of these reports, it is suggested that the treatments
against hypoxia are useful for suppressing the progression of
CKD.
The 5/6 nephrectomized rats we used in this study are
a typical model of progressive renal disease. The initial
change in this model causes increasing glomerular capillary
pressure associated with a relative decrease in the expansion
of eﬀerent arterioles, resulting in glomerular hyperﬁltration
and hypertension. Glomerular hyperﬁltration activates the
renin-angiotensin system, eventually leading to glomerular
sclerosis [19]. However, it has been reported recently that
the deteriorationof renal function in this model is correlated
with an interstitial damage ratherthan aglomerular damage,
and that chronic tissue hypoxia due to the initial reduction
of blood ﬂow causes the progression of renal failure [12].
Furthermore, it has been reported that the continuous
infusion of dimethyloxalylglycine (DMOG), an activator of
HIF, suppressed the increase of proteinuria in this model
[20].
There have been some reports regarding the protective
eﬀects of hachimijiogan on renal function. Hachimijiogan
had antihypertensive and renal-protective eﬀects on Dahl
salt-sensitive hypertensive rats, and its mechanism was sus-
pected to enhance the production of prostaglandin E2 [21].
Hachimijiogan had protective eﬀects on diabetic nephropa-
thy rats induced by streptozotocin injection, with its mecha-
nismbeingsuspectedofimprovinglipidmetabolism,glucose
metabolism, and oxidative stress [22]. Hachimijiogan had
renal-protective eﬀects by improving oxidative stress and
suppressing expression of ﬁbronectin and TGF-β in sponta-
neously diabetic nephropathy rats [10]. Hachimijiogan also
had renal-protective eﬀects on 5/6 nephrectomized rats by
a mechanism thought to reduce uremic toxins associated
with oxidative stress [11]. Morroniside is a main component
of Corni Fructus, which is contained in hachimijiogan, and






























































































































































































Figure 2: Measurement of renal cortical hypoxia-related factors in remnant kidney treated with hachimijiogan. The volume of HIF-1α
protein of the four 5/6Nx groups increased signiﬁcantly compared to that ofthe shamgroup, andthat ofthe high-dosehachimijiogangroup
increased signiﬁcantly compared to that of the control group (a). The mRNA levels of VEGF and Glut-1 of the high-dose hachimijiogan




versus sham group, #P <. 05, ##P <. 01 versus control group.
nephropathy rats by inhibiting the production of advanced
glycation end product and oxidative stress [23].
In this study, the levels of BUN, s-Cre, and urinary
protein excretion of the control group were signiﬁcantly
higher than those of the sham group whereas the level of
Ccr of the control group signiﬁcantly decreased compared
to that of the sham group. The HIF-1α protein level of the
control group increased compared to that of the sham group
one week after nephrectomy, as previously reported [12].
On the other hand, administration of high-dose hachim-
ijiogan signiﬁcantly reduced urinary protein excretion and
elevated the HIF-1α protein level in the renal cortex.
Therefore, it was suggested that hachimijiogan had an
activating eﬀect on HIF. This was also supported by the
observations of increased VEGF mRNA and Glut-1 mRNA.
Immunohistological examination of renal tubular epithelial
cellsalsoshowed anincreaseinHIF-1αbytheadministration
of hachimijiogan.
Administration of candesartan cilexetil, which has renal-
protective eﬀects [24, 25], signiﬁcantly decreased urinary
protein excretion. However, the HIF-1α protein level and
the expressions of VEGF mRNA and Glut 1 mRNA did not
increase by candesartan cilexetil administration. It had been
reported that HIF activation in renal tissue decreases by the
administration of candesartan cilexetil [12]. It is supposed
that the main mechanism contributing to the attenuation of
proteinuria by the administration of ARB is a reduction in
glomerular capillary pressure, as previously reported [26].
It has already been reported that oxidative stress
increased in patients with CKD [27]. In the state of uremia,
d u et ot h ei n c r e a s eo fr e a c t i v eo x y g e ns p e c i e si nt h ev a s c u l a r
endothelium,a reductioninglutathione[28]an danin cr eas e
inreleasingreactiveoxygenspeciesfromleukocytes[29]have
been reported. It has also been reported that the activation
of the renin-angiotensin system suppresses the expression
of super oxide dismutase (SOD) [30]. This oxidative stress
has been reported to have the possibility of inhibiting
the activation of HIF [31]. Therefore, the involvement of
oxidative stress was examined by measuring urinary 8-
OHdG. The results showed that, compared with the sham
group, the control group had a signiﬁcantly increased level
of urinary 8-OHdG, and the hachimijiogan and candesartan
cilexetil groups had signiﬁcantly decreased levels of urinary
8-OHdG.Theantioxidanteﬀectsofhachimijiogan havebeen
reported [10, 11]. Although ARB has also been reported
to have antioxidant activity [32], the HIF activation in
the candesartan cilexetil group did not increase in this
study. Therefore, the mechanism of increasing HIF of the
hachimijiogan group was considered to be a direct eﬀect of
hachimijiogan.
There are various reports about natural products that
have an eﬀect on HIF activation [33]. Concerning phenolic
compounds, quercetin, contained in red wine, has been
reported to have the eﬀect of HIF activation on cultured
murine brain endothelial cells in normoxia [34]. Green tea
extract and its major component epigallocatechin gallate
(EGCG) have been reported to activate HIF in human
prostatecancercells(PC-3ML) byinhibiting thedegradation
with PHD [35]. However, EGCG has also been reported to
have a suppressive eﬀect on HIF activation in HeLa cells and
HepG2 cells by inhibiting the PI3K-AKT-mTOR pathway
[36]. It is suggested that the activations of HIF and VEGF
depend on the kinds of cultured cells or culture conditions.
Moreover, there are as yet few reports on the study of the





















































Figure 3: Immunohistochemical studies showed that the expression of HIF-1α of the high-dose hachimijiogan group increased compared
to that of the control group (a–e). The black arrow indicates an HIF-1α-positive cell stained brown, and the white arrow indicates an HIF-
1α-negative cell stained blue. The number of HIF-1α-positive cells in the high-dose hachimijiogan group increased signiﬁcantly compared
to that in the control group. (a) sham, (b) control, (c) low-dose hachimijiogan, (d) high-dose hachimijiogan, (e) candesartan cilexetil.
(magniﬁcation 400x, scale bar: 100μm), (f) Comparison with percentage of HIF-1α-positive cells/ﬁeld in the every group. Data represent
mean ± S.D.
∗P <. 05,














Figure 4: Hypothetical representation of the eﬀects of hachimijio-
gan on renal dysfunction.
5.Conclusion
It has been suggested that hachimijiogan has a renal-
protective eﬀect through the inﬂuence of HIF activation. We
summarized our hypothetical representation that explains
the eﬀectsof hachimijiogan on renal dysfunction in Figure 4.
Further experiments are needed to determine the active
components and the mechanisms of the activation of HIF,
and to study the long-term eﬀects of hachimijiogan in
vivo. Meanwhile, in terms of renal treatment via HIF, the
hachimijiogan treatment is considered as a new therapeutic
tool in addition to the existing renal treatments.
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